[1]董 朴,蔡福景,张 东,等.胆维他片对肝纤维化大鼠肝中抗氧化体系的影响[J].医学信息,2019,32(18):138-139.[doi:10.3969/j.issn.1006-1959.2019.18.046]
　DONG Pu,CAI Fu-jing,ZHANG Dong,et al.Effect of Danweiita Tablet on Antioxidant System in Liver of Rats with Hepatic Fibrosis[J].Journal of Medical Information,2019,32(18):138-139.[doi:10.3969/j.issn.1006-1959.2019.18.046]
点击复制

胆维他片对肝纤维化大鼠肝中抗氧化体系的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年18期
页码:
138-139
栏目:
药物与临床
出版日期:
2019-09-15

文章信息/Info

Title:
Effect of Danweiita Tablet on Antioxidant System in Liver of Rats with Hepatic Fibrosis
文章编号:
1006-1959（2019）18-0138-02
作者:
董 朴; 蔡福景; 张 东; 吴金国
温州医学院附属第三医院感染科，浙江 瑞安 325200
Author(s):
DONG Pu; CAI Fu-jing; ZHANG Dong; WU Jin-guo
Department of Infectious Diseases,the Third Affiliated Hospital,Wenzhou Medical College,Ruian 325200,Zhejiang,China
关键词:
胆维他片; 肝纤维化; 氧化及抗氧化体系
Keywords:
Key words：Gallbladder tablets; Liver fibrosis; Oxidation and antioxidant system
分类号:
R575
DOI:
10.3969/j.issn.1006-1959.2019.18.046
文献标志码:
A
摘要:
目的 探讨胆维他片对肝纤维化大鼠肝中抗氧化体系的影响。方法 选取30只大鼠按照随机数字表法分为肝纤维化模型组、胆维他片组和正常对照组，每组10只。除正常对照组外，其余各组均要求制备大鼠肝纤维化模型。正常对照组和肝纤维化模型组不给药，胆维他片组于造模开始给予灌胃给药，其余组给予蒸馏水灌胃，于第12周测定肝中丙二醛（MDA）、抗氧化体系的过氧化氢酶（CAT）、超氧化物歧化酶（SOD）、谷胱甘肽（GSH），同时采用Masson's染色肝组织胶原行纤维半定量评估纤维化的程度。结果 纤维化模型组和胆维他片组CAT、SOD、GSH低于正常对照组，MDA高于正常对照组，差异有统计学意义（P＜0.05）；胆维他片组CAT、SOD、GSH均高于纤维化模型组，MDA低于纤维化模型组，差异有统计学意义（P＜0.05）。纤维化模型组和胆维他片组肝纤维化分期高于正常对照组，差异有统计学意义（P＜0.05）；胆维他片组肝纤维化分期低于纤维化模型组，差异有统计学意义（P＜0.05）。结论 胆维他片能有效降低肝纤维化肝内的脂质过氧化，促进肝内氧化及抗氧化体系的恢复，具有减轻肝纤维化的作用。
Abstract:
Abstract：Objective To investigate the effect of Danweita Tablet on the antioxidant system in the liver of rats with hepatic fibrosis.Methods 30 rats were randomly divided into the liver fibrosis model group, the biliary tablet group and the normal control group, with 10 rats in each group. Except the normal control group, the other groups were required to prepare a rat liver fibrosis model. The normal control group and the liver fibrosis model group were not administered. The bilisitis tablets group was administered with intragastric administration at the beginning of modeling, and the other groups were given distilled water for intragastric administration. The liver malondialdehyde (MDA) and anti-drug were measured at the 12th week. The oxidation system of catalase (CAT), superoxide dismutase (SOD), glutathione (GSH), and Masson's stained liver tissue collagen fibers were used to semi-quantitatively assess the degree of fibrosis.Results The CAT, SOD and GSH in the fibrosis model group and the bilisitis tablet group were lower than those in the normal control group, and the MDA was higher than the normal control group,the difference was statistically significant (P<0.05). The CAT, SOD and GSH in the biliary tablet group were all significant. Compared with the fibrosis model group, the MDA was lower than the fibrosis model group,the difference was statistically significant (P<0.05). The fibrosis model group and the gallbladder tablet group had higher liver fibrosis stage than the normal control group, the difference was statistically significant (P<0.05). The gallbladder tablet group had lower liver fibrosis stage than the fibrosis model group,the difference was statistically significant (P<0.05). Conclusion Gallivir tablets can effectively reduce lipid peroxidation in liver fibrosis, promote liver oxidation and recovery of antioxidant system, and reduce liver fibrosis.

参考文献/References:

[1]Sánchez-Valle V,Chávez-Tapia NC,Uribe M,et al.Role of oxidative stress and molecular changes in liver fibrosis:a review[J].Curr Med Chem,2012,19(28):4850-4860. [2]许有信.复方阿嗪米特肠溶片与胆维他片治疗慢性胆囊炎合并腹胀的疗效比较[J].中国处方药,2015,13(5):83-84. [3]陶小红,邱皓,吕晓云.内质网应激相关蛋白在肾纤维化大鼠肾组织中的表达[J].甘肃科技,2019,35(6):99-101. [4]夏婷,张瑾,姚佳慧.氧化应激在酒精性肝病中作用机制的研究进展[J].中国药理学通报,2017,33(10):1353-1356. [5]Luangmonkong T,Suriguga S,Mutsaers HAM,et al.Targeting Oxidative Stress for the Treatment of Liver Fibrosis[J].Rev Physiol Biochem Pharmacol,2018(175):71-102.

相似文献/References:

[1]王艳欣,孟庆华,朱跃科.非侵入性检查方法评价肝纤维化的研究进展[J].医学信息,2018,31(03):40.[doi:10.3969/j.issn.1006-1959.2018.03.014]
　WANG Yan-xin,MENG Qing-hua,ZHU Yue-ke.Progress in Evaluation of Liver Fibrosis by Non-invasive Methods[J].Journal of Medical Information,2018,31(18):40.[doi:10.3969/j.issn.1006-1959.2018.03.014]
[2]李顶春,李 武.Wnt信号通路与肝纤维化[J].医学信息,2018,31(09):4.[doi:10.3969/j.issn.1006-1959.2018.09.002]
　LI Ding-chun,LI Wu.Wnt Signaling Pathway and Hepatic Fibrosis[J].Journal of Medical Information,2018,31(18):4.[doi:10.3969/j.issn.1006-1959.2018.09.002]
[3]艾迎春,迟男男,杜景峰,等.芪参二莲汤对肝纤维化大鼠基质金属蛋白酶-1及 抑制因子的影响[J].医学信息,2018,31(15):140.[doi:10.3969/j.issn.1006-1959.2018.15.045]
　AI Ying-chun,CHI Nan-nan,DU Jing-feng,et al.Effects of Qishenerlian Decoction on Matrix Metalloproteinase-1 and Its Inhibitory Factors in Rats with Hepatic Fibrosis[J].Journal of Medical Information,2018,31(18):140.[doi:10.3969/j.issn.1006-1959.2018.15.045]
[4]皮青文.恩替卡韦抗病毒治疗对慢性乙肝肝硬化患者肝功能及肝硬化程度的影响[J].医学信息,2022,35(15):121.[doi:10.3969/j.issn.1006-1959.2022.15.028]
　PI Qing-wen.Effect of Entecavir Antiviral Therapy on Liver Function and Degree of Liver Cirrhosis in Patients with Chronic Hepatitis B Cirrhosis[J].Journal of Medical Information,2022,35(18):121.[doi:10.3969/j.issn.1006-1959.2022.15.028]
[5]林思萍,龚先琼.中药单体调控TGF-β1/Smads信号通路抗纤维化的研究[J].医学信息,2019,32(21):30.[doi:10.3969/j.issn.1006-1959.2019.21.011]
　LIN Si-ping,GONG Xian-qiong.Study on Anti-Fibrosis of TGF-β1/Smads Signaling Pathway Regulated by Chinese Medicine Monomer[J].Journal of Medical Information,2019,32(18):30.[doi:10.3969/j.issn.1006-1959.2019.21.011]
[6]张小雨,严 艳.自身免疫性肝炎合并自身免疫性疾病的特征研究[J].医学信息,2020,33(02):89.[doi:10.3969/j.issn.1006-1959.2020.02.024]
　ZHANG Xiao-yu,YAN Yan.Study on the Characteristics of Autoimmune Hepatitis Combined with Autoimmune Diseases[J].Journal of Medical Information,2020,33(18):89.[doi:10.3969/j.issn.1006-1959.2020.02.024]
[7]邹克平.超声实时剪切波弹性成像对血吸虫病肝纤维化的诊断效能分析[J].医学信息,2022,35(18):150.[doi:10.3969/j.issn.1006-1959.2022.18.042]
　ZOU Ke-ping.Analysis of Diagnostic Efficacy of Ultrasound Shear Wave Elastography in Schistosomiasis Liver Fibrosis[J].Journal of Medical Information,2022,35(18):150.[doi:10.3969/j.issn.1006-1959.2022.18.042]
[8]郭 冶,卢凤美,刘东璞.肝纤维化发病机制及大黄酸对肝纤维化的作用[J].医学信息,2020,33(12):27.[doi:10.3969/j.issn.1006-1959.2020.12.010]
　GUO Ye,LU Feng-mei,LIU Dong-pu.The Pathogenesis of Hepatic Fibrosis and the Effect of Rhein on Hepatic Fibrosis[J].Journal of Medical Information,2020,33(18):27.[doi:10.3969/j.issn.1006-1959.2020.12.010]
[9]徐勇平.舒肝宁注射液治疗晚期血吸虫病肝纤维化的效果及其对血清指标的影响[J].医学信息,2020,33(24):151.[doi:10.3969/j.issn.1006-1959.2020.24.043]
　XU Yong-ping.Shuganning Injection in the Treatment of Advanced Schistosomiasis Liver Fibrosis and Its Influence on Serum Indexes[J].Journal of Medical Information,2020,33(18):151.[doi:10.3969/j.issn.1006-1959.2020.24.043]
[10]叶 亮,赵永忠.FIB-4、APRI及肝纤维指标对乙型肝炎肝硬化的诊断价值[J].医学信息,2021,34(05):85.[doi:10.3969/j.issn.1006-1959.2021.05.024]
　YE Liang,ZHAO Yong-zhong.The Diagnostic Value of FIB-4,APRI and Liver Fiber Indexes in Hepatitis B Liver Cirrhosis[J].Journal of Medical Information,2021,34(18):85.[doi:10.3969/j.issn.1006-1959.2021.05.024]

更新日期/Last Update: 2019-09-15